• Korean Chemical Engineering Research
• /
• v.48 no.5
• /
• pp.574-582
• /
• 2010

In this study, the possibility of a quartz crystal micro-balance(QCM) modification of crystallization of L-Penicillamine and D-Penicillamine with a Vapor Diffused Molecular Assembly Technique and its application to the R-(-)-Mandelic acid and S-(+)- Mandelic acid measurement was investigated. The 3-dimensional structures of L-Penicillamine and D-Penicillamine on the surface of QCM were verified to be different from each other through QCM and AFM analyses. The D-Penicillamine modified QCM had specific recognition to the R-(-)-Mandelic acid, but L-Penicillamine modified QCM had no specificity to the R-(-)-Mandelic acid and S-(+)- Mandelic acid. From these results, it was known that the QCM could be modified with various selective meterials via VDMA, and the chiral isomer such as a Mandelic acid isomer could be detected by using a modified QCM.

• Childhood Kidney Diseases
• /
• v.8 no.2
• /
• pp.250-255
• /
• 2004

Wilson's disease is an autosomal recessive disorder characterized by degenerative changes in the brain, liver, and cornea. Treatment includes D-penicillamine, trientine, and zinc sulfate. D-penicillamine has been used frequently as first line therapy for Wilson's disease. However, nephrotoxicity can occur after D-penlcillamlne treatment. Among them membranous glomerulopathy is the most common histological abnormality but minimal change lesions have also been reported. Nephrotic syndrome is a late complication of D-penicillamine treatment but very rarely can occur within 2 months after treatment of D-penicillamine. We report the early development of minimal change nephrotic syn,frome in a 3-year-old'girl with Wilson's disease 3 weeks after initiation of D-penicillamine.

• Journal of Preventive Medicine and Public Health
• /
• v.15 no.1
• /
• pp.131-137
• /
• 1982

For the purpose of the curative effects of oral D-penicillamine in lead poisoning, D-penicillamine was orally administered to 7 lead poisoned workers which were employed in glaze product industry dealing with the lead oxide ($Pb_3O_4$). The doses of D-penicillamine was 1,200mg per day which was administered by oral 7days schedules, taking for 5 days and stopping for the following 2days, repeatedly during 3 months period. (All the poisoned workers started working again in that industry after 1 month treatment, and were treated by oral D-penicillamine for 2 months still being exposed to contaminated environment.) In order to evaluate the curative effects of D-penicillamine, 10gm of whole blood and 24 hours urine were collected every 14 days during the curative period for laboratory analysis(hemoglobin, blood lead, urine $\sigma$-aminolevulinic acid, urine coproporphyrin, and urine lead levels) with the observation of the clinical symptoms. The results were as follows; 1. Oral D-penicillamine effected good curative results as that hemoglobin, blood lead, urine $\sigma$-aminolevulinic acid, and urine coproporphyrin levels were decreased below the critical level within 1 month treatment. 2. After re-exposure, oral D-penicillamine effected to some extent as that urine lead level was decreased below the critical level after 3 months treatment with disappearence of the clinical symptoms after 2 months treatment. However, the curative effects of oral D-penicillamine in the lead exposure state is questionable since increasement of blood lead level and remarkable decreasement of urine lead level after 3 months treatment can be observed.

• Journal of Preventive Medicine and Public Health
• /
• v.9 no.1
• /
• pp.87-94
• /
• 1976

In order to study the chelating action of d-penicillamine on lead and the possibility of its application to the provocation test for diagnosis of lead poisoning, urinary excretion of lead was measured from 24-hour urine samples before, during and after administration of d-penicillamine by oral route for 5 days on 18 lead workers. The results were as follows: 1. Oral d-penicillamine 600 mg/day raised the excretion of urinary lead by approximately 3 times as compared with initial urinary lead level. 2. Initial urinary lead level was the better indicator of urinary lead excretion in d-penicillamine administration than initial blood lead ${\delta}-ALA$ and hemoglobin level. 3. Oral d-penicillamine may be quite useful in provocation test for lead poisoning.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.5 no.2
• /
• pp.206-211
• /
• 2002

Wilson's disease is a treatable autosomal recessive inherited disorder of copper metabolism due to mutation of the copper transporting gene. The basic strategy of treatment is to reduce the amount of copper in the liver and other tissues by administering both a low copper diet and copper-chelating agents. D-penicillamine is the first choice as a copper-chelating agent. Some serious side effects could occur in 3~5% of all patients following D-penicillamine therapy. We report a 19 year-old male with Wilson's disease who developed nephrotic syndrome 6 months after the initiation of D-penicillamine therapy. Prednisolone was administered to control nephrotic syndrome and D-penicillamine was switched to trientine. Urinary remission was achieved within a week and maintained thereafter. Nephrotic syndrome was proven to be MCNS by kidney biopsy.

• Journal of the Korean Chemical Society
• /
• v.30 no.5
• /
• pp.475-482
• /
• 1986

Rates and equilibriurn of complex formation between $Ni^{2+}$ and D-penicillamine have been investigated in aqueous solutions. Kinetic study on the complex formation were performed in the pH range of 8∼9 by the use of pressure-jump technique. D-Penicillamine coordinates to the nickel(II) ion utilizing sulfur and nitrogen as donor atoms in the high pH condition (pH 9.2). However, in the pH range of 8.25∼9.07, the stepwise stability constant becomes drastically reduced and the undissociated mercapto group does not participate in bonding. The rate-determining step of the complexation reaction is found to be the release of a water molecule from the inner-coordination sphere of $Ni^{2+}$ ion.

• Journal of Preventive Medicine and Public Health
• /
• v.12 no.1
• /
• pp.43-48
• /
• 1979

For the purpose of further health control, D-penicillamine was orally administered to 8 persons who were employed in lead industry and suspected lead intoxication routine industrial health examination. The does of D-penicillamine was 600 mg per day and was administered orally in every other 5 days, For the laboratory analysis 24 hours urine and 10 gm of whole blood were collected every day. The results were as follows; 1. It was found that mean urinary lead excretion per day was 446.5 g/l and 394.98 g/l, respectively during the first 5-day and the second 5-day administration with D-penicillamine. 2. Mean lead excretion per day was $130.56{\pm}66.42g/l$ after first 5-day administration and $159.28{\pm}104.44g/l$ after second 5-day administration with D-penicillamine. 3. The level of urinary lead excretion after administration increased 3 to 4 times than that before administration with D-peniciilamine. 4. Blood and urinary lead level investigated after 6 months were $44.4{\pm}10.2g/100g\;and\;72.7{\pm}29.7\;g/l$ for the eight persons.

• Bulletin of the Korean Chemical Society
• /
• v.14 no.4
• /
• pp.444-449
• /
• 1993

Anaerobic oxidation of D-penicillamine by Fe(III) in acidic solution has been studied kinetically by the use of stopped-flow system. The reaction is biphasic with a rapid complexation of 1: 1 complex, $Fepen^+$ (pen= D-penicillamine dianion) which is then internally reduced to Fe(II) and disulfide. Rates of both the complexation and the redox process are pH dependent and also are affected by the presence of chloride ion. Different from the reaction of Cu(II) with D-penicillamine, partially oxidized mixed-valence complex is not formed even transiently in this reaction.

• Journal of Pharmaceutical Investigation
• /
• v.20 no.2
• /
• pp.73-78
• /
• 1990

A sensitive fluorometric method using 9-fluorenylmethyl pentafluorophenyl carbonate (FMPC) as the fluorescent labeling agent was developed to determine D-penicillamine (D-PA). The fluorophore had excitation and emission wavelengths of 260 nm and 313 nm, respectively. After derivatization, the fluorescent product was separated, and quantified by spectrofluorometry. The derivative was highly fluorescent and stable. Optimum condition for the reaction was investigated. A linear response was obtained over the range of $4.0{\times}10^{-7}-5.0{\times}10{-6}\;M$ with the correlation coefficient of 0.999 (n=6). The procedure described was successfully applied to the determination of the dosage forms of capsule with the recovery of $98.62{\pm}0.57%$ (150 mg), $98.36{\pm}0.57%$, (250 mg).

• Journal of the Korean Chemical Society
• /
• v.35 no.4
• /
• pp.429-431
• /
• 1991